Cybin Inc Stock Price, News & Analysis

Cybin (NYSE American: CYBN) announced that Chief Medical Officer Amir Inamdar will participate in a panel at the 2025 Milken Institute Future of Health Summit in Washington, D.C., held November 4–6, 2025.

Panel: Reimagining Mental Health: Innovation at the Intersection of Care and Technology. Date: Wednesday, November 5, 2025. Time: 2:00–3:00 PM ET. The live panel will be accessible via webcast, and an archived recording will be posted on Cybin’s investor relations Events & Presentations page.

Cybin (NYSE American: CYBN) closed a registered direct offering on October 31, 2025 raising aggregate gross proceeds of US$175,009,911.45.

The Company issued 22,277,750 common shares and 4,605,500 pre-funded warrant(s) at US$6.51 each; each security includes 0.35 common share purchase warrant exercisable at US$8.14 until the earlier of June 30, 2027 or certain trial/data or acceleration triggers. Placement agents included Jefferies, TD Cowen, and Cantor. Net proceeds are intended to repay outstanding unsecured convertible debentures held by High Trail, advance CYB003/CYB004/CYB005 programs, and for working capital and general corporate purposes.

Cybin (NYSE American: CYBN) announced a registered direct offering of 22,277,750 common shares and pre-funded warrant equivalents at US$6.51 per share/pre-funded warrant for aggregate gross proceeds of US$175,009,911.45. Each security includes 0.35 warrant exercisable at US$8.14 until June 30, 2027 or earlier on specified trial or market triggers. Proceeds are intended to repay outstanding High Trail convertible debentures in full, advance CYB003, CYB004, and CYB005 clinical programs, and for working capital. The offering is led by Jefferies, TD Cowen, and Cantor and is expected to close on October 31, 2025, subject to exchange approvals and customary conditions.

Cybin (NYSE American:CYBN) has provided updates on its neuropsychiatry platform and clinical milestones. The company has completed enrollment of 36 participants in its Phase 2 study of CYB004 (deuterated DMT) for Generalized Anxiety Disorder, with topline data expected in Q1 2026.

The company is advancing CYB003, its deuterated psilocin analog, in Phase 3 studies for major depressive disorder (MDD). The APPROACH study aims to enroll 220 patients across 45 U.S. clinical sites, while the EMBRACE study targeting 330 participants is set to begin in Q4 2025.

Cybin boasts a robust intellectual property portfolio with 100+ granted patents and 250+ pending applications. The company has partnered with Thermo Fisher Scientific for U.S.-based commercial-scale manufacturing and Osmind for commercial preparation across 800+ psychiatry clinics.

Cybin (NYSE American:CYBN), a clinical-stage neuropsychiatry company, announced its participation in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit. The company's Chief Medical Officer Amir Inamdar and Chief Business Officer George Tziras will engage in a fireside chat on September 17, 2025, at 9:20 a.m. ET.

The presentation will be accessible through a webcast, with a replay available on Cybin's investor relations website under the Events & Presentations section.

Cybin (NYSE American:CYBN) has completed enrollment for its Phase 2 clinical trial evaluating CYB004, a proprietary deuterated DMT program, for treating Generalized Anxiety Disorder (GAD). The study has enrolled 36 participants to evaluate safety and efficacy over a 12-week period.

The company expects to release top-line data in Q1 2026. CYB004 aims to address a significant unmet need, as GAD affects 6.8 million people in the US alone, with approximately 50% not responding to current approved treatments. The drug offers convenient intramuscular dosing and is supported by robust patent protection.

Cybin (NYSE American:CYBN), a clinical-stage neuropsychiatry company, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. George Tziras, the Company's Chief Business Officer, will engage in a fireside chat on September 8, 2025, at 11:00 a.m. ET.

The presentation will be accessible via webcast, with a replay available on Cybin's investor relations website under the Events & Presentations section.

Cybin (NYSE American:CYBN), a clinical-stage neuropsychiatry company, announced its participation in the upcoming Cantor Global Healthcare Conference. The company's Chief Medical Officer, Dr. Amir Inamdar, will engage in a fireside chat scheduled for September 5, 2025, at 10:20 a.m. ET.

The presentation will be accessible via live webcast, with an archived version available on Cybin's investor relations website under the Events & Presentations section.

Cybin (NYSE American:CYBN) announced significant leadership changes as CEO Doug Drysdale steps down effective September 2, 2025. The company's Co-Founder and President, Eric So, has been appointed as Interim Chief Executive Officer by the Board of Directors.

So, who brings over 20 years of experience as an owner, operator, and investor, will focus on advancing Cybin's clinical pipeline, particularly the development of CYB003 and CYB004. The Board has established a committee to conduct a search for a permanent CEO who will lead the company through its commercialization phase.

The transition comes as Cybin continues its mission to transform mental healthcare through innovative neuropsychiatry treatments, supported by its clinical progress, regulatory recognition, and strategic partnerships.